$2,371,884 $2,581,035 $2,199,113
========== ========== ==========
Liabilities and
Shareholders' Equity
Current liabilities
Accounts payable $232,875 $235,922 $216,030
Notes payable - - 10,169
Payroll and related taxes 51,949 70,977 49,910
Accrued customer programs 52,789 53,419 45,537
Accrued liabilities 49,435 55,055 38,162
Current deferred income taxes 16,120 24,493 18,864
Current portion of
long-term debt 15,869 20,095 17,598
Current liabilities of
discontinued operations 18,975 31,659 21,493
------ ------ ------
Total current
liabilities 438,012 491,620 417,763
Non-current liabilities
Long-term debt, less
current portion 875,000 895,095 697,598
Non-current
deferred income
taxes 133,955 138,158 111,483
Other non-current liabilities 74,770 112,396 102,472
Non-current liabilities of
discontinued operations 9,391 10,051 9,233
----- ------ -----
Total non-
current
liabilities 1,093,116 1,155,700 920,786
Shareholders' equity
Preferred stock, without par
value, 10,000 shares authorized - - -
Common stock, without par value,
200,000 shares authorized 448,589 488,537 498,002
Accumulated other
'/>"/>SOURCE Perrigo Company Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Related medicine news :1.
Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service2.
Perrigo Company to Host Analyst Meeting on September 18, 20073.
Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution4.
Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution5.
Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory6.
Perrigo Company Will Release First Quarter Fiscal 2008 Results on November 1, 20077.
Perrigo Company Announces Dividend Increase8.
Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval9.
Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference10.
Perrigo Acquires UK OTC Store Brand Supplier11.
Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend